BioCentury
ARTICLE | Clinical News

CHS-1701: Phase I data

February 8, 2016 8:00 AM UTC

Coherus said a double-blind, U.S. Phase I trial in 303 healthy volunteers showed that 2 sequential subcutaneous doses of 6 mg CHS-1701 met the co-primary endpoints based on the development of neutrali...